Merkel cell carcinoma (MCC) is a rare and aggressive cancer with a case fatality rate of 33%. Delayed diagnoses of MCC are common, which results in patients often presenting at advanced stages, said Manisha Thakuria, MD, at the 2015 World Cutaneous Malignancies Congress. The optimal care of MCC is debated. [ Read More ]
Current approaches to the treatment and follow-up of patients with malignant melanoma, including those with brain metastases, were reviewed by speakers at the 2015 World Cutaneous Malignancies Congress. Approach to the BRAF-Positive Patient Melanoma is an immunogenic oncogene-driven cancer, said Grant McArthur, MB, BS, PhD, in explaining the rationale for [ Read More ]
Genetic testing in metastatic melanoma should include testing for all actionable mutations in exon 15, said Grant McArthur, MB, BS, PhD, at the 2015 World Cutaneous Malignancies Congress. Testing at the time of disease progression is not yet ready for routine clinical use. Test the Metastases In metastatic melanoma, tumor [ Read More ]
Genetic testing in metastatic melanoma should include testing for all actionable mutations in exon 15, said Grant McArthur, MB, BS, PhD, at the 2015 World Cutaneous Malignancies Congress. Testing at the time of disease progression is not yet ready for routine clinical use. Test the Metastases In metastatic melanoma, tumor [ Read More ]
Current approaches to the treatment and follow-up of patients with malignant melanoma, including those with brain metastases, were reviewed by speakers at the 2015 World Cutaneous Malignancies Congress. Approach to the BRAF-Positive Patient Melanoma is an immunogenic oncogene-driven cancer, said Grant McArthur, MB, BS, PhD, in explaining the rationale for [ Read More ]
Emerging concepts in the treatment of melanoma include new definitions for stage I/II and stage III disease, new surgical paradigms that incorporate systemic neoadjuvant therapy for advanced disease, and locoregional treatment with intralesional therapies that have both local and distant effects, said presenters at the 2015 World Cutaneous Malignancies Congress. [ Read More ]
Emerging approaches in advanced melanoma include adjuvant targeted therapy/immunotherapy, new immunotherapy treatment algorithms, and novel vaccines. The progress on each was reviewed by presenters at the 2015 World Cutaneous Malignancies Congress. State-of-the-Art Adjuvant Therapy Despite advancements in progression-free survival (PFS) in treatment-naive unresectable melanoma with the use of targeted agents [ Read More ]
Several therapies for advanced nonmelanoma malignancies have recently taken hold or have shown encouraging potential, said presenters at the 2015Â World Cutaneous Malignancies Congress. Basal Cell Carcinoma Basal cell carcinoma (BCC) represents a spectrum of disease, from curable with surgery to locally advanced or metastatic disease, for which surgery is inappropriate. [ Read More ]
Understanding the clinical presentations and molecular biology of cutaneous malignancies is essential to applying therapy to clinical practice. At the 2015 World Cutaneous Malignancies Congress, experts discussed contributors to the pathogenesis of melanoma, basal cell carcinoma, cutaneous T-cell lymphoma, and Merkel cell carcinoma, including genetic drivers. Melanoma New concepts in [ Read More ]
Using less stringent evaluation criteria for sonidegib for the treatment of locally advanced basal cell carcinoma (BCC) improved the complete response (CR) rate observed in the registration trial known as BOLT. These data, presented in poster format, were reported by Michael R. Migden, MD, at the 2015 World Cutaneous Malignancies [ Read More ]
